Albireo Pharma Inc Beta
What is the Beta of Albireo Pharma Inc?
The Beta of Albireo Pharma Inc is 0.00
What is the definition of Beta?
BETA indicates whether a stock is more or less volatile than the market as a whole. A beta less than 1 indicates that the stock is less volatile than the market, while a beta more than 1 indicates that the stock is more volatile. Volatility is measured as the fluctuation of the price around the mean.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with beta similar to Albireo Pharma Inc
- Vision Marine Technologies has Beta of 0.00
- Ely Gold Royalties has Beta of 0.00
- Glacier Lake Resources has Beta of 0.00
- Magnum Mining and Exploration has Beta of 0.00
- Africa Opportunity Fund has Beta of 0.00
- Fulcrum Utility Services has Beta of 0.00
- Albireo Pharma Inc has Beta of 0.00
- Gullewa has Beta of 0.00
- S.A.L. Steel has Beta of 0.00
- Andina Acquisition III has Beta of 0.00
- Andina Acquisition III has Beta of 0.00
- Brilliant Acquisition has Beta of 0.00
- Indokem has Beta of 0.00